[go: up one dir, main page]

BR9812127A - Arilpiridazinonas como inibidores da biossìntese de prostagleina endoperóxido h sintase - Google Patents

Arilpiridazinonas como inibidores da biossìntese de prostagleina endoperóxido h sintase

Info

Publication number
BR9812127A
BR9812127A BR9812127-8A BR9812127A BR9812127A BR 9812127 A BR9812127 A BR 9812127A BR 9812127 A BR9812127 A BR 9812127A BR 9812127 A BR9812127 A BR 9812127A
Authority
BR
Brazil
Prior art keywords
cox
inhibitors
prostaglein
endoperoxide
cyclooxygenase
Prior art date
Application number
BR9812127-8A
Other languages
English (en)
Inventor
Lawrence A Black
Anwer Basha
Teodozyjkolasa
Michael E Kort
Huaqing Liu
Catherine M Mccarty
Meena V Patel
Jeffrey J Rohde
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of BR9812127A publication Critical patent/BR9812127A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/18—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"ARILPIRIDAZINONAS COMO INIBIDORES DA BIOSSìNTESE DE PROSTAGLEINA ENDOPERóXIDO H SINTASE" A presente invenção divulga compostos de piridazinona, os quais são inibidores da ciclooxigenase (COX) e, em particular, são inibidores seletivos da ciclooxigenase-2 (COX/2). A COX-2 é a isoforma capaz de ser induzida associada com a inflamação, em oposição à isoforma constitutiva, a ciclooxigenase-1 (COX-1), que é uma enzima "zeladora" importante em muitos tecidos, incluindo o trato gastrointestinal (GI) e os rins. A seletividade destes compostos para a COX-2 minimiza os efeitos colaterais GI e renais não desejados, vistos com as drogas antiinflamatórias não-esteroidais (NSAIDs) atualmente vendidas.
BR9812127-8A 1997-08-22 1998-08-10 Arilpiridazinonas como inibidores da biossìntese de prostagleina endoperóxido h sintase BR9812127A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91702397A 1997-08-22 1997-08-22
PCT/US1998/016479 WO1999010331A1 (en) 1997-08-22 1998-08-10 Arylpyridazinones as prostaglandin endoperoxide h synthase biosynthesis inhibitors

Publications (1)

Publication Number Publication Date
BR9812127A true BR9812127A (pt) 2000-07-18

Family

ID=25438243

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9812127-8A BR9812127A (pt) 1997-08-22 1998-08-10 Arilpiridazinonas como inibidores da biossìntese de prostagleina endoperóxido h sintase

Country Status (8)

Country Link
EP (1) EP1007515A1 (pt)
BR (1) BR9812127A (pt)
CA (1) CA2299300C (pt)
CO (1) CO4970740A1 (pt)
SA (1) SA98190764B1 (pt)
TW (1) TWI232216B (pt)
WO (1) WO1999010331A1 (pt)
ZA (1) ZA987555B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307047B1 (en) * 1997-08-22 2001-10-23 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
US6525053B1 (en) * 1997-08-22 2003-02-25 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
NZ504045A (en) 1997-11-19 2001-06-29 Kowa Co Pyridazine derivatives with inhibitory action against interleukin-1-beta production
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
AU756275B2 (en) 1998-08-14 2003-01-09 Nihon Nohyaku Co., Ltd. Pyridazinone derivatives
PL198503B1 (pl) * 1998-10-27 2008-06-30 Abbott Lab Związki pirydazynonowe, kompozycje farmaceutyczne je zawierające oraz ich zastosowanie
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
JP2000247959A (ja) 1999-02-26 2000-09-12 Kowa Co ピリダジン−３−オン誘導体及びこれを含有する医薬
NZ519781A (en) 1999-12-23 2004-04-30 Nitromed Inc Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
US6664256B1 (en) 2000-07-10 2003-12-16 Kowa Co., Ltd. Phenylpyridazine compounds and medicines containing the same
ITMI20010733A1 (it) 2001-04-05 2002-10-05 Recordati Chem Pharm Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
BR0306988A (pt) * 2002-01-18 2004-11-23 Pharmacia Corp Piridazinonas substituìdas como inibidores de p38
CA2518227A1 (en) 2003-03-18 2004-09-30 Kowa Co., Ltd Water-soluble phenylpyridazine derivative and medicine containing the same
DK1534305T3 (da) 2003-05-07 2007-02-05 Osteologix As Behandling af brusk-/knoglelidelser med vandoplöselige strontiumsalte
WO2005007632A1 (en) * 2003-07-18 2005-01-27 Pharmacia Corporation Substituted pyridazinones as inhibitors of p38
DE602005014359D1 (de) 2004-06-09 2009-06-18 Sumitomo Chemical Co Pyridazinverbindung und deren verwendung
PL1775290T3 (pl) 2004-06-28 2011-04-29 Sumitomo Chemical Co Związek pirydazynowy i jego zastosowanie
MX2007014114A (es) 2005-05-10 2008-03-14 Intermune Inc Derivados de piridona para modular el sistema de proteina cinasa activada por estres.
BRPI0616655A2 (pt) * 2005-10-03 2011-06-28 Ono Pharmaceutical Co composto heterocìclico contendo nitrogênio e aplicação farmacêutica do mesmo
WO2007080720A1 (ja) 2005-12-07 2007-07-19 Sumitomo Chemical Company, Limited ピリダジン化合物およびその用途
WO2007066601A1 (ja) 2005-12-07 2007-06-14 Sumitomo Chemical Company, Limited ピリダジン化合物及びその用途
DE102007008839A1 (de) 2007-02-23 2008-08-28 Bayer Healthcare Ag Verfahren zur Herstellung von 4-(3-Hydroxy-3-methyl-butoxy)-5-[4-(methylsulfonyl)phenyl]-2-arylpyridazin-3(2H)-onen
DE102007008843A1 (de) 2007-02-23 2008-08-28 Bayer Healthcare Ag Verfahren zur Herstellung von 4,5-Dihalogen-2-aryl-2H-pyridazin-3-onen
DE102007008840A1 (de) 2007-02-23 2008-08-28 Bayer Healthcare Ag Neue polymorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-methyl-1-butoxy)-5-[4-methylsulfonyl)phenyl]-3(2H)-pyridazinon (FHMP)
DE102007020690A1 (de) 2007-05-03 2008-11-06 Bayer Healthcare Ag Neue amorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-mehtyl-1-butoxy)-6[4-methylsulfonyl)phenyl]-3(2H)-pyridazinon (FHMP)
DE102007020689A1 (de) 2007-05-03 2008-11-06 Bayer Healthcare Ag Neue polymorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-methyl-1-butoxy-5-[4-methylsulfonyl)phenyl]3/2H)-pyridazinon (FHMP)
US8304413B2 (en) 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
WO2013073577A1 (ja) 2011-11-15 2013-05-23 アステラス製薬株式会社 ジヒドロキシ芳香族へテロ環化合物
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CN106459042B (zh) 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类
US11096924B2 (en) 2016-09-07 2021-08-24 Trustees Of Tufts College Combination therapies using immuno-dash inhibitors and PGE2 antagonists
WO2022195579A1 (en) 2021-03-15 2022-09-22 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988009675A1 (en) * 1987-06-05 1988-12-15 Medicis Corporation Inhibition of arachidonic acid metabolism
AU691673B2 (en) * 1994-11-14 1998-05-21 Dow Agrosciences Llc Pyridazinones and their use as fungicides
US5622948A (en) * 1994-12-01 1997-04-22 Syntex (U.S.A.) Inc. Pyrrole pyridazine and pyridazinone anti-inflammatory agents

Also Published As

Publication number Publication date
ZA987555B (en) 1999-02-23
CA2299300A1 (en) 1999-03-04
EP1007515A1 (en) 2000-06-14
WO1999010331A1 (en) 1999-03-04
CO4970740A1 (es) 2000-11-07
CA2299300C (en) 2007-04-17
SA98190764B1 (ar) 2006-08-06
TWI232216B (en) 2005-05-11

Similar Documents

Publication Publication Date Title
BR9812127A (pt) Arilpiridazinonas como inibidores da biossìntese de prostagleina endoperóxido h sintase
BR9914858A (pt) Inibidores de biosìntese sintase h de endoperóxido de prostaglandina
ATE319691T1 (de) Prostaglandin endoperoxyde h synthase biosynthese inhibitoren
Grishanova et al. Aryl hydrocarbon receptor in oxidative stress as a double agent and its biological and therapeutic significance
Reddy et al. C-Phycocyanin, a selective cyclooxygenase-2 inhibitor, induces apoptosis in lipopolysaccharide-stimulated RAW 264.7 macrophages
Feldman et al. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity?
BRPI0011172B8 (pt) derivados do 4,5-diaril-3(2h)-furanona como inibidores de ciclooxigenase-2
Kim et al. The conventional nonsteroidal anti-inflammatory drug sulindac sulfide arrests ovarian cancer cell growth via the expression of NAG-1/MIC-1/GDF-15
Ramalho et al. The search for new COX-2 inhibitors: a review of 2002–2008 patents
Huguenin et al. Evaluation of the antitumoral potential of different nitric oxide-donating non-steroidal anti-inflammatory drugs (NO-NSAIDs) on human urological tumor cell lines
Herschman et al. Cyclooxygenase 2 (COX-2) as a target for therapy and noninvasive imaging
Bhat et al. Novel sulindac derivatives: Synthesis, characterisation, evaluation of antioxidant, analgesic, anti-inflammatory, ulcerogenic and COX-2 inhibition activity
Osmaniye et al. Design, synthesis and biological evaluation of new N‐acyl hydrazones with a methyl sulfonyl moiety as selective COX‐2 inhibitors
Biava Introduction to COX inhibitors
Rayyan et al. The role of NSAIDs in the prevention of colon cancer
Theoduloz et al. Inhibition of key enzymes in the inflammatory pathway by hybrid molecules of terpenes and synthetic drugs: In vitro and in silico studies
Nath et al. Flurbiprofen benzyl nitrate (NBS-242) inhibits the growth of A-431 human epidermoid carcinoma cells and targets β-catenin
TR200000478T2 (tr) Prostaglandin endoperoksit H sentaz biyosentezi inhibitörleri olarak arilpiridazinonlar.
Tavares The effects of meloxicam, indomethacin or NS‐398 on eicosanoid synthesis by fresh human gastric mucosa
Deray Renal and cardiovascular effects of non-steroidal anti-inflammatories and selective cox 2 inhibitors
Dammann Preferential COX-2 inhibition: its clinical relevance for gastrointestinal non-steroidal anti-inflammatory rheumatic drug toxicity
Berg et al. Pharmacology of a selective cyclooxygenase-2 inhibitor, HN-56249: a novel compound exhibiting a marked preference for the human enzyme in intact cells
Réti et al. Enhancement of 5-fluorouracil efficacy on high COX-2 expressing HCA-7 cells by low dose indomethacin and NS-398 but not on low COX-2 expressing HT-29 cells
Gülcan et al. Marginally designed new profen analogues have the potential to inhibit cyclooxygenase enzymes
UY26279A1 (es) Ciclooxigenasa-1(cox-1) y ciclooxigenasa-2 (cox-2) caninas

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE DIANTE DO QUE FOI EXPOSTO, OPINO POR NAO ACOLHER A PRESENTACAO DO INTERESSADO E, CONSIDERANDO QUE NAO FORAM APRESENTADOS ARGUMENTOS PERTINENTES, CONCLUI- SE QUE O PEDIDO EM LIDE NAO APRESENTA REQUISITOS QUE JUSTIFIQUEM O SEU REEXAME

B12B Appeal against refusal [chapter 12.2 patent gazette]